STRATA Skin Sciences, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Dolev Rafaeli
- Full Time Employees
- 106
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 5 Walnut Grove Drive Horsham PA United States of America 19044
- IPO Date
- Nov 3, 2005
- CIK
- 0001051514
- Website
- strataskinsciences.com
- Similar Companies
- Business
- STRATA Skin Sciences, Inc. develops, commercializes and markets medical devices for the in-office treatment of dermatologic conditions including psoriasis, vitiligo, atopic dermatitis, eczema and acne; core products comprise the XTRAC excimer laser and Pharos excimer lasers that deliver targeted 308nm UVB light therapy, VTRAC excimer lamp systems offering similar therapeutic efficacy with lamp-based design and reliability, and TheraClearX Acne Therapy System utilizing FDA-cleared photopneumatic technology combining vacuum and pulsed broadband light for mild-to-moderate inflammatory, comedonal and pustular acne. The company operates through Dermatology Recurring Procedures and Dermatology Procedures Equipment segments, deriving primary revenue from equipment usage fees via its Partnership Program that provides installation, training, maintenance, customer support and co-op advertising without upfront purchases; it serves dermatology clinics principally in the United States with select international distribution including CE Mark approval for certain products in the European Union. Founded in 1989 and headquartered in Horsham, Pennsylvania, STRATA Skin Sciences, formerly MELA Sciences, Inc., acquired PhotoMedex Inc. in 2015 to expand its portfolio. Recent developments include a $2.42 million registered direct offering of common stock priced at-market in September 2025 to institutional investors; renewal of exclusive distribution agreements; a preliminary court injunction in November 2024 against LaserOptek prohibiting U.S. marketing of competing Pallas laser systems, resulting in over 20 former competitors partnering with STRATA for XTRAC and generating over $1 million in annualized revenue; and American Medical Association CPT Board reaffirmation in May 2025 of exclusive excimer laser coding through January 2027 for up to 30 dermatologic conditions.
New Peer-Reviewed Publication Confirms Unprecedented Response Rates for STRATA's Excimer Laser Combined with JAK Inhibitors in Pediatric Vitiligo
Short Interest in Strata Skin Sciences, Inc. (NASDAQ:SSKN) Rises By 89.2%
Hims & Hers Health (NYSE:HIMS) & Strata Skin Sciences (NASDAQ:SSKN) Head-To-Head Analysis
Critical Comparison: Clover Health Investments (NASDAQ:CLOV) and Strata Skin Sciences (NASDAQ:SSKN)
STRATA Skin Sciences Confirms Nasdaq Delisting
SSKN Stock Falls Despite Meta-Analysis Backs Excimer Laser's Efficacy
Johns Hopkins Dermatology Expands Advanced Care for Inflammatory and Autoimmune Skin Conditions with Addition of XTRAC® Excimer Laser
Reviewing Clover Health Investments (NASDAQ:CLOV) & Strata Skin Sciences (NASDAQ:SSKN)
STRATA Skin Sciences Highlights Meta-Analysis Confirming Clinical Efficacy of 308 nm Excimer Laser for Plaque Psoriasis
Laseroptek America Files Counterclaims Alleging Anticompetitive and Unfair Business Practices in Ongoing Litigation with Strata Skin Sciences
Contrasting Butterfly Network (NYSE:BFLY) & Strata Skin Sciences (NASDAQ:SSKN)
Analyzing Strata Skin Sciences (NASDAQ:SSKN) and Outset Medical (NASDAQ:OM)
STRATA Skin Sciences Showcases XTRAC® and TheraclearX® at TeraCILAD 2025 — Reports Early Adoption Momentum in Mexico
Head-To-Head Analysis: Decision Diagnostics (OTCMKTS:DECN) vs. Strata Skin Sciences (NASDAQ:SSKN)
STRATA Skin Sciences, Inc. (SSKN) Q3 2025 Earnings Call Transcript
STRATA Skin Sciences Announces CMS Recognition of Expanded CPT Codes for Inflammatory and Autoimmune Dermatologic Conditions with Company Anticipating Wider Excimer Adoption Ahead Of 2027 CPT Expansion
STRATA Skin Sciences to Report Third Quarter 2025 Financial Results on November 13, 2025 and Provide Corporate Update
Excimer Laser Demonstrates Promising Results in Treating Rare Variant of Cutaneous Lymphoma, Mycosis Fungoides
Marking Eczema Awareness Month – Clinical Research Validates Strata Skin Sciences' XTRAC® Excimer Laser as a Breakthrough Therapy for Localized Atopic Dermatitis
STRATA Skin Sciences Receives Continued Validation for its Personalized Approach with New Published Study Highlighting XTRAC® Excimer Laser Treatment Combined with a Topical Drug in Psoriasis